Dauricine attenuates ovariectomized-induced bone loss and RANKL-induced osteoclastogenesis via inhibiting ROS-mediated NF-κB and NFATc1 activity. 2024

Xixi Lin, and Guixin Yuan, and Bin Yang, and Chunlan Xie, and Zhigao Zhou, and Ying Liu, and Zhijuan Liu, and Zuoxing Wu, and Yoshie Akimoto, and Na Li, and Ren Xu, and Fangming Song
The First Affiliated Hospital of Xiamen University-ICMRS Collaborating Center for Skeletal Stem Cells, State Key Laboratory of Cellular Stress Biology, School of Medicine, Xiamen University, Xiamen, Fujian, 361100, China; Xiamen Key Laboratory of Regeneration Medicine, Fujian Provincial Key Laboratory of Organ and Tissue Regeneration, School of Medicine, Xiamen University, Xiamen, 361100, China.

BACKGROUND Osteoclast plays an important role in maintaining the balance between bone anabolism and bone catabolism. The abnormality of osteoclast is closely related to osteolytic bone diseases such as osteoporosis, rheumatoid arthritis and tumor bone metastasis. OBJECTIVE We aim to search for natural compound that may suppress osteoclast formation and function. METHODS In this study, we assessed the impact of Dauricine (Dau) on the formation and function of osteoclasts in vitro, as well as its potential in preventing bone loss in an ovariectomy mouse model in vivo. METHODS Multiple in vitro experiments were carried out, including osteoclastogenesis, podosomal belt formation, bone resorption assay, RNA-sequencing, real-time quantitative PCR, ROS level detection, surface plasmon resonance assay, luciferase assay and western blot. To verify the effect in vivo, an ovariectomized mouse model (OVX model) was constructed, and bone parameters were measured using micro-CT and histology. Furthermore, metabolomics analysis was performed on blood serum samples from the OVX model. RESULTS In vitro experiments demonstrated that Dau inhibits RANKL-induced osteoclastogenesis, podosomal belt formation, and bone resorption function. RNA-sequencing results revealed that Dau significantly suppresses genes related to osteoclast. Functional enrichment analysis indicated that Dau's inhibition of osteoclasts may be associated with NF-κB signaling pathway and reactive oxygen metabolism pathway. Molecular docking, surface plasmon resonance assay and western blot analysis further confirmed that Dau inhibits RANKL-induced osteoclastogenesis by modulating the ROS/NF-κB/NFATc1 pathway. Moreover, administration of Dau to OVX-induced mice validated its efficacy in treating bone loss disease. CONCLUSIONS Dau prevents OVX-induced bone loss by inhibiting osteoclast activity and bone resorption, potentially offering a new approach for preventing and treating metabolic bone diseases such as osteoporosis. This study provides innovative insights into the inhibitory effects of Dau in an in vivo OVX model and elucidates the underlying mechanism.

UI MeSH Term Description Entries

Related Publications

Xixi Lin, and Guixin Yuan, and Bin Yang, and Chunlan Xie, and Zhigao Zhou, and Ying Liu, and Zhijuan Liu, and Zuoxing Wu, and Yoshie Akimoto, and Na Li, and Ren Xu, and Fangming Song
February 2020, Scientific reports,
Xixi Lin, and Guixin Yuan, and Bin Yang, and Chunlan Xie, and Zhigao Zhou, and Ying Liu, and Zhijuan Liu, and Zuoxing Wu, and Yoshie Akimoto, and Na Li, and Ren Xu, and Fangming Song
September 2013, European journal of pharmacology,
Xixi Lin, and Guixin Yuan, and Bin Yang, and Chunlan Xie, and Zhigao Zhou, and Ying Liu, and Zhijuan Liu, and Zuoxing Wu, and Yoshie Akimoto, and Na Li, and Ren Xu, and Fangming Song
February 2023, Free radical biology & medicine,
Xixi Lin, and Guixin Yuan, and Bin Yang, and Chunlan Xie, and Zhigao Zhou, and Ying Liu, and Zhijuan Liu, and Zuoxing Wu, and Yoshie Akimoto, and Na Li, and Ren Xu, and Fangming Song
January 2021, Frontiers in pharmacology,
Xixi Lin, and Guixin Yuan, and Bin Yang, and Chunlan Xie, and Zhigao Zhou, and Ying Liu, and Zhijuan Liu, and Zuoxing Wu, and Yoshie Akimoto, and Na Li, and Ren Xu, and Fangming Song
January 2021, Frontiers in pharmacology,
Xixi Lin, and Guixin Yuan, and Bin Yang, and Chunlan Xie, and Zhigao Zhou, and Ying Liu, and Zhijuan Liu, and Zuoxing Wu, and Yoshie Akimoto, and Na Li, and Ren Xu, and Fangming Song
May 2024, iScience,
Xixi Lin, and Guixin Yuan, and Bin Yang, and Chunlan Xie, and Zhigao Zhou, and Ying Liu, and Zhijuan Liu, and Zuoxing Wu, and Yoshie Akimoto, and Na Li, and Ren Xu, and Fangming Song
April 2019, Journal of cellular physiology,
Xixi Lin, and Guixin Yuan, and Bin Yang, and Chunlan Xie, and Zhigao Zhou, and Ying Liu, and Zhijuan Liu, and Zuoxing Wu, and Yoshie Akimoto, and Na Li, and Ren Xu, and Fangming Song
December 2010, Journal of immunology (Baltimore, Md. : 1950),
Xixi Lin, and Guixin Yuan, and Bin Yang, and Chunlan Xie, and Zhigao Zhou, and Ying Liu, and Zhijuan Liu, and Zuoxing Wu, and Yoshie Akimoto, and Na Li, and Ren Xu, and Fangming Song
January 2022, Frontiers in pharmacology,
Xixi Lin, and Guixin Yuan, and Bin Yang, and Chunlan Xie, and Zhigao Zhou, and Ying Liu, and Zhijuan Liu, and Zuoxing Wu, and Yoshie Akimoto, and Na Li, and Ren Xu, and Fangming Song
January 2019, Theranostics,
Copied contents to your clipboard!